Laser-based home healthcare R&D Korean company MVITRO announced on December 17 that it has been named a “Featured Exhibitor” in the “Digital Health” category at CES 2025, the world’s largest consumer electronics and IT trade show, set to take place next January.

MVITRO will showcase ORTIV, its pain-free laser blood sampling and glucose monitoring device, recently approved for sale by the U.S. Food and Drug Administration (FDA).

ORTIV uses laser technology instead of disposable needles, enabling pain-free blood sampling and glucose measurement. Its ability to reduce pain to a “painless” level has garnered attention not only in South Korea but also in the U.S., Japan, and Europe.

MVITRO was selected as one of eight notable companies in the Digital Health category, alongside organizations like the AgeTech Collaborative by AARP and Dassault Systemes.

CEO Young-woo Lee of MVITRO shared, “Since presenting ORTIV as a prototype at CES 2023, we’ve connected with numerous buyers interested in our pain-free laser blood sampling technology. With over 25 confirmed meetings and our recent FDA approval, we expect many discussions to lead to contracts this time.”

In the U.S., MVITRO has signed a sales contract for ORTIV with Applied Science Inc. (ASI), a supplier of medical equipment to blood banks. In South Korea, a leading pharmaceutical company is preparing to secure exclusive domestic distribution rights, while Japan’s global diagnostic enzyme manufacturer Toyobo has commissioned MVITRO to develop laser-based diagnostic tools for various diseases.

MVITRO expects regulatory approval from South Korea’s Ministry of Food and Drug Safety in the first quarter of next year, with plans to launch ORTIV in the domestic market shortly after.